JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the competitive BTK inhibitor market. Latest Ratings for BGNE Date Firm Action From To ...